Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Viela Bio - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how the study drug (VIB4920) given with Belatacept (an Immunosuppressive drug) can help stop rejection of a kidney transplant.
What is the Condition Being Studied?
Kidney Transplant

Who Can Participate in the Study?

- Adults 18-70
- Never had a kidney transplant

Age Group

What is Involved?

If you choose to join this study you will:
- Complete physical
- Give blood samples
- Get ECG (looking at electrical activity of the heart)
- Complete follow-up visits for 15 months (every other week for 3 months and then once a month)

Study Details

Full Title
A PHASE 2A SINGLE-ARM, PROSPECTIVE, OPENLABEL PILOT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUAL COSTIMULATION BLOCKADE WITH VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULTS RECEIVING A KIDNEY TRANSPLANT
Principal Investigator
Kidney/Pancreas Transplant Surgeon
Protocol Number
IRB: PRO00103332
NCT: NCT04046549
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698